Alumis reports Phase 2b SLE trial results for envudeucitinib
Compartilhar
Alumis (NASDAQ:ALMS) reported Phase 2b LUMUS trial results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus, with the overall study population not meeting the primary endpoint.
